METAREM is a master protocol that encompasses multiple therapeutic sub-protocols, each involving distinct interventions. Accordingly, the description of the intervention will be specified within each for neoplasm metastasis
A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set
Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.
Put together by software, not yet checked by a person
Why this status
24 Feb 2026: Trial registered, NCT07431073
21 Aug 2026: Trial started, NCT07431073
The trials
NCT07431073: Immunotherapy Master Trial for Advanced Cancers
State
Under way
Phase
Phase 2
People
275 planned
Started
21 Aug 2026
Primary completion
Dec 2028
Arms
Single Arm immunotherapy in Advanced Metastatic Cancers
Results
None posted
24 Feb 2026: Trial registered
21 Aug 2026: Trial started
How the status changed
19 Nov 2026: First set: Phase 2 trial
About the treatment
Kind of treatment: Drug.
Registries searched: ClinicalTrials.gov, through 17 Nov 2026.